Suggested Topics within your search.
Suggested Topics within your search.
- English language 10
- Management 8
- Report writing 8
- Research 8
- Methodology 7
- Rhetoric 7
- methods 7
- Psychology 6
- Economic policy 5
- Medicine 5
- Economic conditions 4
- Economics 4
- Education 4
- Handbooks, manuals, etc 4
- Health 4
- Law reports, digests, etc 4
- Mass media 4
- Microbiology 4
- Pharmacology 4
- Psychological aspects 4
- Statistical methods 4
- Study and teaching 4
- Anesthesiology 3
- Computer-assisted instruction 3
- Criminal law 3
- Cultural property 3
- Differential equations 3
- Economic aspects 3
- Economic development 3
- Educational technology 3
-
201221
-
201222
-
201223
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events
Published 2025-01-01“…Methods The incidence of MACE (i.e., adjudicated cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), DVT, and PE was assessed in adults who received ≥ 1 dose of IXE across 25 randomized clinical trials (17 PsO, 4 PsA, 4 axSpA). …”
Get full text
Article -
201224
-
201225
-
201226
Ten pressure points in primary care during COVID-19: findings from an international narrative review
Published 2025-01-01Get full text
Article -
201227
Outcomes of patients after successful left ventricular assist device explantation: a EUROMACS study
Published 2020-06-01Get full text
Article -
201228
-
201229
The growth of eel fed with different protein level and protein-energy ratio
Published 2015-10-01Get full text
Article -
201230
-
201231
-
201232
-
201233
Brucella osteoarthritis: recent progress and future directions
Published 2025-02-01Get full text
Article -
201234
-
201235
-
201236
-
201237
-
201238
-
201239
-
201240
Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials
Published 2025-02-01“…For instance, when comparing PKI treatment with other treatments, median OS and PFS showed no significant difference (-0.78 months, 95 % CI, −2.12–0.55, p = 0.25; −0.23 months, 95 % CI, −0.79–0.34, p = 0.43, respectively), and similar non-significant results were observed in the pooled analyses (OS: HR = 0.89, 95 % CI, 0.59–1.32, p = 0.55; PFS: HR = 0.83, 95 % CI, 0.63–1.11, p = 0.21).Despite these overall negative findings, some data indicate improved clinical outcomes in a subset of GBM patients treated with certain PKIs (i.e., regorafenib) and encourage further research to identify PKIs with better blood-brain barrier penetration and lower risk for resistance development.…”
Get full text
Article